Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naïve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir

REFERENCES

• Law MG, Früs-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 2006;7(4):218–230.
   PubMed Web of Science ®Google Scholar
• Currier JS. Update on cardiovascular complications in HIV infection. Top HIV Med. 2009;17(3):98–103.
   PubMedGoogle Scholar
• Früs-Moller N, Reiss P, Sabin CA, et al. Class of antiretro-viral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17)1 723–1735.
   Web of Science ®Google Scholar
• Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus rito-navir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445–456.
   PubMed Web of Science ®Google Scholar
• Ganesan A, Benning L, Golub ET, et al. Serum lipid pro-files among patients initiating ritonavir-boosted atazana-vir versus efavirenz-based regimens. AIDS Res Ther. 2009;6:13.
   PubMedGoogle Scholar
• Wilson PWF, Abbott RD, Castelli WP. High-density lipo-protein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988;8(6):737–741.
   PubMedGoogle Scholar
• Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26(4):847.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antünflammatory properties of HDL. Circ Res. 2004;95(8):764–772.
   PubMed Web of Science ®Google Scholar
• van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: Significance for car-diovascular risk. The IDEAL and EPIC-Norfolk Studies. J Am Coll CardioL 2008;51(6):634–642.
   PubMed Web of Science ®Google Scholar
• Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin LipidoL 2010;21(4):312–318.
   PubMed Web of Science ®Google Scholar
• Duprez DA, Kuller LH, Tracy R, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Ath-erosclerosis. 2009;207(2):524–529.
   PubMed Web of Science ®Google Scholar
• Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Rid-ker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipo-proteins in predicting incident cardiovascular disease in women. Circulation. 2009;119(7):931–939.
   PubMed Web of Science ®Google Scholar
• Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic reso-nance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. Arterio-scler Thromb Vasc BioL 2002;22(7):1175–1180.
   PubMed Web of Science ®Google Scholar
• Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle sub-classes predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs high-density lipoprotein intervention trial. Circulation. 2006;113(12)1 556–1563.
   Web of Science ®Google Scholar
• Lyons TJ, Jenkins AJ, Zheng D, et al. Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabet Med. 2006;23(9):955–966.
   PubMed Web of Science ®Google Scholar
• Stein JH, Komarow L, Cotter BR, et al. Lipoprotein changes in HIV-infected antiretroviral-naive individuals after starting class-sparing antiretroviral therapy: ACTG Study A5152s. J Clin LipidoL 2008;2(6):464–471.
   PubMed Web of Science ®Google Scholar
• Albini L, Cesana BM, Malta D, et al. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naïve HIV-infected patients after tenofovir/ emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr 201259(1):18–30.
   Google Scholar
• European Medicines Agency (EMEA). ICH Topic E 6 (R1) Guideline for Good Clinical Practice. July 2002. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf.
   Google Scholar
• Ballantyne CM, Hoogeveen RC. Role of lipid and lipopro-tein profiles in risk assessment and therapy. Am Heart J. 2003;146:227–233.
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J CardioL 2005;96(3): 399–404.
   PubMed Web of Science ®Google Scholar
• Hanak V, Munoz J, Teague J, Stanley A, Bittner V. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein pheno-type B. Am J CardioL 2004;94(2):219–222.
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Pro-gram (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25): 3143–3421.
   PubMed Web of Science ®Google Scholar
• Shlay JC, Bartsch G, Peng G et al. Long-term body com-position and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strat-egy. J Acquir Immune Defic Syndr. 2007;44(5):506–517.
   PubMed Web of Science ®Google Scholar
• Fontas E, van Leth F, Sabin CA et al. Lipid profiles in HIV-infected patients receiving combination antiretrovi-ral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189(6): 1056–1074.
   PubMed Web of Science ®Google Scholar
• Young J, Weber R, Rickenbach M et al. Lipid profiles for antiretroviral-naive patients starting Pl- and NNRTI-based therapy in the Swiss HIV Cohort Study. Antivir Ther. 2005;10(5):585–591.
   PubMed Web of Science ®Google Scholar
• Franssen R, Sankatsing RR, Hassink E, et al. Nevirapine increases high-density lipoprotein cholesterol concentra-tion by stimulation of apolipoprotein A-I production. Arte-rioscler Thromb Vasc Biol. 2009;29(9):1336–1341.
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Andrade-Villanueva J, et al. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). HIV Med. 2011;12(6):374–382.
   PubMed Web of Science ®Google Scholar
• van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirap-ine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001 ;15(18):2407–2414.
   PubMed Web of Science ®Google Scholar
• Asztalos BF, Guppies LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ. High-density lipoprotein sub-population profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc BioL 2004;24(11):2181–2187.
   PubMed Web of Science ®Google Scholar
• Asztalos BF, Collins D, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ. Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardio-vascular events in the Veterans Affairs High-Density Lipo-protein Intervention Trial. Metabolism. 2008;57(1):77–83.
   PubMed Web of Science ®Google Scholar
• Worm SW, Kamara DA, Reiss P, et al. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS. 201125(12)1 497–1500.
   Web of Science ®Google Scholar
• Cullen P. Evidence that triglycerides are an indepen-dent coronary heart disease risk factor. Am J Cardiol. 2000;86:943–949.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyc-eride-rich lipoproteins and high-density lipoprotein cho-lesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 201132(11):1345–1361.
   Google Scholar
• Cheng AYY, Leiter LA. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr Opin CardioL 2006 ;21(4):400–404.
   PubMed Web of Science ®Google Scholar
• Patroni A, Carosi G, Castelli F, et al. Effect of highly active antiretroviral therapy (HAART) and hepatitis C co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. HIV Clin Trials. 2002;3(6):451–461.
   PubMedGoogle Scholar